UTAA-09

N/A

Report date: 2026/05/14 20:00:28
First In Class

Base Information

Drug NameUTAA-09
Drug Alias Namerecombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector (PersonGen Biotherapeutics)UTAA09 cells therapy (PersonGen Biotherapeutics)T cell injection targeting CD19 chimeric antigen receptor (PersonGen Biotherapeutics)UTAA09 Injection (PersonGen Biotherapeutics)UTAA-09 cells therapy (PersonGen Biotherapeutics) +[9] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapy > Chimeric antigen receptor Vδ1T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapy > Chimeric antigen receptor Vδ1T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-T
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A